
    
      This is an otherwise open-label, single-arm study (Part A) that includes a 2-week,
      double-blind, placebo controlled, randomized drug withdrawal period (Part B) followed by a 3
      week blinded maintenance or re-titration (Part A resumed), and then a maintenance period.
      This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with
      tics associated with TS who have previously completed participation in any of the parent
      studies (SD-809-C-17 [Phase 1b], TV50717-CNS 30046 [Phase 2/3], or TV50717-CNS 30060 [Phase
      3]).
    
  